Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)‘s stock had its “outperform” rating reaffirmed by stock analysts at Royal Bank Of Canada in a report issued on Tuesday. They presently have a $54.00 price target on the stock. Royal Bank Of Canada’s price target points to a potential upside of 45.36% from the stock’s previous close.

Several other analysts have also recently issued reports on PCRX. Canaccord Genuity reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pacira Pharmaceuticals in a research note on Monday, May 15th. Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, May 24th. ValuEngine raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. BidaskClub raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $53.00.

Pacira Pharmaceuticals (NASDAQ PCRX) opened at 37.15 on Tuesday. The company has a 50-day moving average price of $38.74 and a 200 day moving average price of $44.82. Pacira Pharmaceuticals has a 52-week low of $29.95 and a 52-week high of $58.95. The stock’s market cap is $1.50 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.06. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business had revenue of $70.90 million for the quarter, compared to analysts’ expectations of $73.37 million. During the same period in the prior year, the company posted $0.21 EPS. The firm’s revenue was up 1.9% on a year-over-year basis. On average, analysts expect that Pacira Pharmaceuticals will post ($0.17) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Stock Rating Reaffirmed by Royal Bank Of Canada” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/07/pacira-pharmaceuticals-inc-pcrx-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

In other news, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $36.75, for a total value of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares in the company, valued at approximately $783,216. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David M. Stack sold 28,885 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total transaction of $1,050,547.45. Following the completion of the transaction, the chief executive officer now owns 159,164 shares in the company, valued at $5,788,794.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,390 shares of company stock worth $1,215,480. Company insiders own 6.60% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. lifted its holdings in Pacira Pharmaceuticals by 5.2% during the 2nd quarter. Principal Financial Group Inc. now owns 5,466 shares of the company’s stock worth $261,000 after buying an additional 270 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Pacira Pharmaceuticals by 9.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after buying an additional 302 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Pacira Pharmaceuticals by 12.2% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after buying an additional 303 shares in the last quarter. Denver Investment Advisors LLC lifted its holdings in Pacira Pharmaceuticals by 6.8% during the 2nd quarter. Denver Investment Advisors LLC now owns 6,850 shares of the company’s stock worth $327,000 after buying an additional 435 shares in the last quarter. Finally, Amalgamated Bank lifted its holdings in Pacira Pharmaceuticals by 12.7% during the 2nd quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock worth $240,000 after buying an additional 566 shares in the last quarter.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.